Shanghai Xiao Fang PharmaceuticalLtd Past Earnings Performance
Past criteria checks 2/6
Shanghai Xiao Fang PharmaceuticalLtd has been growing earnings at an average annual rate of 8.1%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 7.5% per year. Shanghai Xiao Fang PharmaceuticalLtd's return on equity is 16.5%, and it has net margins of 41.7%.
Key information
8.1%
Earnings growth rate
14.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 7.5% |
| Return on equity | 16.5% |
| Net Margin | 41.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Shanghai Xiao Fang PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 472 | 197 | 63 | 19 |
| 31 Dec 23 | 472 | 204 | 60 | 16 |
| 31 Dec 22 | 457 | 175 | 56 | 14 |
| 31 Dec 21 | 402 | 126 | 94 | 14 |
| 31 Dec 20 | 361 | 160 | 40 | 11 |
| 31 Dec 19 | 340 | 142 | 47 | 11 |
Quality Earnings: 603207 has a high level of non-cash earnings.
Growing Profit Margin: 603207's current net profit margins (41.7%) are lower than last year (42%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603207's earnings have grown by 8.1% per year over the past 5 years.
Accelerating Growth: 603207's earnings growth over the past year (0.2%) is below its 5-year average (8.1% per year).
Earnings vs Industry: 603207 earnings growth over the past year (0.2%) exceeded the Pharmaceuticals industry -1.2%.
Return on Equity
High ROE: 603207's Return on Equity (16.5%) is considered low.